Skip to content

Inspection Record

Cangene Corporation — FDA 483 Findings

US FDAInspected 2012-06-21Published 2026-10-27 9 findingsOther quality systemDeviation, CAPA, and investigationEnvironmental monitoring

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

There are no individual reject rates established for each defect category that is classified as(D)(4) The reject rate established is cumulative for all (b)(4) defects.

2Deviation, CAPA, and investigation

Deviation 109218 was initiated on June 7, 2010 for HepaGamB Finished Goods lot (b)(4) having been EMPEYEE(S) SIGHATURE——Z

3Deviation, CAPA, and investigation

The firm’s deviation control system is inadequate in that it fails to adequately assess the classification of .

4Other quality system

There is no defined change out period for product contact flexible hoses used in manufacturing.

5Environmental monitoring

The SOP for Growth Promotion of media used for’environmental monitoring is incomplete in that it does not specify the length oftime test articles should be incubated.

6Other quality system

Not all lots ofproduct that fail the Acceptable Quality Limit (AQL) after the initial (B)(4) inspection is performed are reinspected under tightened limits for both the additional (6)(4) reinspection performed by production or the AQL performed by Quality.

8Other quality system

SOP 25.026.0002.01.00 defines a On Oiled JO Ment A The printing, and circulation of such documents are not always controlled: A.

9Other quality system

There is a lack of assurance that there is adequate control over critical documents including, but not limited to, Policies, Standard Operating Procedures (SOPs), Work Instructions (WIs) Forms, Electronic Templates (ETs) Drawingsand Manuals.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Cangene Corporation company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.